Literature DB >> 18083669

The physical, social and psychological impact of priapism on adult males with sickle cell disorder.

Gulen Addis1, Rachel Spector, Elizabeth Shaw, Luhanga Musumadi, Cathy Dhanda.   

Abstract

Priapism is defined as prolonged and painful penile erection that does not subside on orgasm. It is considered to be a urological emergency. However, patients do not always seek prompt medical help. The incidence of priapism is increased by sickle cell disease, where it is a complication of the characteristic sickling of the red blood cells. Little is known about the psychological or social implications of this complication or the strategies that sickle cell patients use to manage it. A qualitative study was carried out in order to investigate these topics. Semi-structured interviews were carried out with adult male patients of the Sickle Cell and Thalassaemia Centre in Birmingham in the UK who experienced priapism. These were subsequently analysed using grounded theory. Ten themes were elicited: first occurrence of priapism, pain, precipitants, emotional consequences, self-management, experience of hospital, impact on work and social life, impact on sexual relationships, erectile dysfunction, and disclosure. The dominant experiences were ones of despair, embarrassment, and isolation. Participants described finding it difficult to disclose priapism, with the result that it was often unreported until late in its course. Attempts to manage priapism at home varied, with there being little consensus on their efficacy. The results are discussed with respect to the healthcare services that cater for these patients.

Entities:  

Mesh:

Year:  2007        PMID: 18083669     DOI: 10.1177/1742395307081505

Source DB:  PubMed          Journal:  Chronic Illn        ISSN: 1742-3953


  9 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.

Authors:  Arthur L Burnett; Uzoma A Anele; Irene N Trueheart; John J Strouse; James F Casella
Journal:  Am J Med       Date:  2014-03-25       Impact factor: 4.965

3.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

4.  Priapism Impact Profile Questionnaire: Development and Initial Validation.

Authors:  Arthur L Burnett; Uzoma A Anele; Leonard R Derogatis
Journal:  Urology       Date:  2015-04-08       Impact factor: 2.649

Review 5.  Testosterone Deficiency in Sickle Cell Disease: Recognition and Remediation.

Authors:  Biljana Musicki; Arthur L Burnett
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

6.  The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study.

Authors:  Shawn M Bediako; Sophie Lanzkron; Marie Diener-West; Gladys Onojobi; Mary C Beach; Carlton Haywood
Journal:  J Health Psychol       Date:  2014-07-04

7.  Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research.

Authors:  Marsha J Treadwell; Kathryn Hassell; Roger Levine; San Keller
Journal:  Clin J Pain       Date:  2014-10       Impact factor: 3.442

8.  External validation of the priapism impact profile in a Jamaican cohort of patients with sickle cell disease.

Authors:  Belinda F Morrison; Wendy Madden; Monika Asnani; Ayodeji Sotimehin; Uzoma Anele; Yuezhou Jing; Bruce J Trock; Arthur L Burnett
Journal:  PLoS One       Date:  2021-10-15       Impact factor: 3.240

9.  Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010.

Authors:  Brandi Dupervil; Scott Grosse; Arthur Burnett; Christopher Parker
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.